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Abstract
 
Immunostimulatory properties of dendritic cells (DCs) are linked to their maturation state. In-
jection of mature DCs rapidly enhances antigen-specific CD4
 
1
 
 and CD8
 
1
 
 T cell immunity in
humans. Here we describe the immune response to a single injection of immature DCs pulsed
with influenza matrix peptide (MP) and keyhole limpet hemocyanin (KLH) in two healthy
subjects. In contrast to prior findings using mature DCs, injection of immature DCs in both
subjects led to the specific inhibition of MP-specific CD8
 
1
 
 T cell effector function in freshly
isolated T cells and the appearance of MP-specific interleukin 10–producing cells. When pre-
and postimmunization T cells were boosted in culture, there were greater numbers of MP-spe-
cific major histocompatibility complex tetramer-binding cells after immunization, but these
had reduced interferon 
 
g 
 
production and lacked killer activity. These data demonstrate the fea-
sibility of antigen-specific inhibition of effector T cell function in vivo in humans and urge
caution with the use of immature DCs when trying to enhance tumor or microbial immunity.
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Introduction
 
Dendritic cells (DCs) are APCs specialized to regulate T
cell immunity (1). DCs normally reside and traffic through
nonlymphoid tissues in an immature form, poised for anti-
gen capture. Inflammatory stimuli are necessary to switch
DCs to an immunostimulatory mode. This process, termed
“maturation,” is associated with changes in DC phenotype
and function, including upregulation of costimulatory and
adhesion molecules and expression of distinct chemokine
receptors (2). Due to their potency as APCs, there is con-
siderable interest in using these cells as adjuvants to enhance
immunity against cancer and viral infections. We and others
have previously shown that injection of antigen-bearing
DCs derived from monocyte precursors and matured ex
vivo using inflammatory stimuli leads to rapid enhancement
 
of CD4
 
1
 
 and CD8
 
1
 
 T cell immunity in humans (3–5).
To examine whether the ex vivo maturation stimulus is
essential for the immune efficacy of a DC vaccine, we initi-
ated a clinical study comparing DCs cultured with or with-
out such a stimulus. DCs were pulsed with KLH and, in
the case of HLA A2.1
 
1
 
 subjects, additionally with HLA
A
 
*
 
0201–restricted influenza matrix peptide (MP). Here we
describe the findings on the first two study subjects injected
with immature DCs.
 
Materials and Methods
 
Study Design.
 
The study was initiated as a randomized 2 
 
3
 
 2
factorial design, comparing a single injection of immature versus
mature DCs administered subcutaneously versus intradermally.
This brief report describes the inhibition of antigen-specific ef-
fector function in the first two subjects (Im1 and Im2) injected
subcutaneously with immature DCs. Two additional subjects re-
ceived an injection of mature DCs, either intradermally (M1) or
subcutaneously (M2). Based on these findings, the study is now
modified to only compare routes of administration of mature
DCs in subsequent subjects.
 
Human Volunteers.
 
Normal healthy adult volunteers were re-
cruited through advertisement. Eligibility and exclusion criteria
were as in a prior study (4) and included age of 18–65 yr and no
clinical evidence of malignancy, chronic infection, or autoimmu-
nity. All subjects signed an informed consent, and the study was
approved by the The Rockefeller University Institutional Re-
view Board.
 
Baseline Studies.
 
All study participants were typed for HLA
A2.1 status and initially followed for a 1–3-mo period, during
which at least two baseline measurements of immune response
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were made. Laboratory tests at baseline to confirm eligibility in-
cluded complete blood count, chemistry profile, hepatitis B and
C and HIV serology, rheumatoid factor, antinuclear antibody
(ANA), urinalysis, chest X-ray, pregnancy test, influenza serol-
ogy, and anergy panel consisting of candida, mumps, and tetanus.
 
Generation and Injection of DCs.
 
DCs were generated from
plastic adherent blood monocyte precursors after in vitro culture
with GM-CSF and IL-4 as described (4) and pulsed with antigens
on day 5 of culture. The antigens were: 10 
 
m
 
g/ml KLH (depyro-
genated; Calbiochem) and 1 
 
m
 
g/ml influenza MP (manufactured
by A. Houghton in the microchemistry facility of the Sloan-Ket-
tering Institute, New York, NY). Autologous monocyte–condi-
tioned medium (50% vol/vol) was added on day 5 of culture as a
maturation stimulus for subjects receiving mature DCs (M1, M2;
reference 4). Two million DCs were injected on day 6 (Im1) or
day 7 (Im2, M1, M2) of culture (see Table I). On the day of in-
jection, the DCs were washed free of antigen, resuspended in
normal saline containing 5% autologous plasma in two 0.1–0.2-
cm
 
3
 
 aliquots, and injected within 30 min of final reconstitution.
The phenotype of the injected DCs was monitored by flow cy-
tometry. All injected DC preparations tested negative for bacte-
rial and fungal contamination.
 
Follow-up and Monitoring.
 
Immune responses were evaluated
1 wk after DC injection and at 1–3-mo intervals thereafter. Both
subjects had a repeat hemogram, rheumatoid factor, ANA, and
influenza serology 1 mo after DC injection.
 
Measurement of Immune Responses.
 
Measurement of immune
response was performed on freshly isolated PBMCs. In addition,
for most assays, cryopreserved pre- and postimmunization speci-
mens were thawed, coded, and assayed together in a blinded
fashion.
 
ELISPOT Assay for Antigen-specific Cytokine (IFN-
 
g
 
, IL-4, IL-
10)-secreting T Cells.
 
Antigen-specific T cells were quantified
using a standard ELISPOT assay as described (4) after overnight
culture in the presence or absence of antigens in plates precoated
with anticytokine (IFN-
 
g
 
, IL-4, or IL-10) antibodies (Mabtech).
Antigens were 1 
 
m
 
g/ml HLA A
 
*
 
0201–restricted peptides from
influenza MP (GILGFVFTL), HIV gag (gag; SLYNTVATL), and
CMV pp65 (NLVPMVATV) as controls. The background reac-
tivity with no peptide in this assay was low (mean 
 
6 
 
SE: 1 
 
6 
 
1
spot-forming cells [SFCs]/2 
 
3 
 
10
 
5
 
 cells). For the detection of in-
fluenza-specific responses, PBMCs were infected with influenza
virus at a multiplicity of infection of 2. For some assays, MP-
pulsed mature DCs were used as APCs (PBMC/DC ratio 30:1).
KLH (10 
 
m
 
g/ml) was also used as an antigen (no protein and su-
perantigen as controls) in some assays. In additional assays, bulk T
 
cells were depleted of CD4
 
1
 
 and CD8
 
1
 
 T cells using magnetic
beads (Miltenyi Biotec) before use in the ELISPOT assays.
 
MHC Tetramer Binding Assays.
 
Soluble influenza MP–HLA
A
 
*
 
0201 tetramers were prepared as described (6), and binding to
tetramers was analyzed by FACS
 
®
 
. Frozen aliquots of PBMCs
from before and after immunization were thawed together and
stained as described (4) with A
 
*
 
0201–MP tetramer at 37
 
8
 
C, both
directly before and after 7-d coculture with autologous MP-
pulsed DCs (unpulsed DCs as controls).
 
Recall T Cell Assays.
 
For recall assays, pre-/postimmuniza-
tion PBMCs were cocultured with freshly generated autologous
mature DCs pulsed with MP (unpulsed DCs as control) at a
PBMC/DC ratio of 30:1 for 7 d. At the end of 7-d culture, MP-
specific T cells were quantified as described earlier (3) using (a)
ELISPOT assay for antigen-specific cytokine–producing cells (af-
ter restimulation on day 7); (b) MHC tetramer binding assay; or
(c) CTL assay. CTL activity was measured in a standard 5-h 
 
51
 
Cr-
release assay at an E/T ratio of 20:1. Targets were T2 cells pulsed
with 1 
 
m
 
g/ml MP or unpulsed T2 cells as controls. Excess cold
K562 cell targets (80:1) were used to inhibit NK-mediated lysis.
 
Antigen-dependent Proliferation.
 
Antigen-dependent prolifera-
tion assays were performed as described, at two PBMC dose lev-
els (3 
 
3
 
 10
 
4
 
 cells per well and 10
 
5
 
 cells per well) in the absence or
presence of graded doses of KLH (0.1–10 
 
m
 
g/ml; reference 4).
Tetanus toxoid and staphylococcal enterotoxin A (SEA) served as
control antigens. For some assays, bulk T cells were depleted of
CD4
 
1
 
 and CD8
 
1
 
 T cells using magnetic beads (Miltenyi Biotec)
before use in proliferation assays.
 
Results
 
Inhibition of MP-specific Effector T Cell Function In Vivo after
DC Injection.
 
Two subjects (Im1 and Im2) received a sin-
gle subcutaneous injection of 2 
 
3
 
 10
 
6
 
 immature DCs
pulsed with the influenza peptide, MP, and KLH (Table I).
All DC injections in this study were well tolerated without
any clinical toxicity and serologic/clinical evidence of
autoimmunity. Before immunization, MP-specific IFN-
 
g
 
–
producing T cells were detectable in both subjects as ex-
pected, because most adults have been exposed to the in-
fluenza virus. However, after DC immunization, there was
a decline in MP-specific IFN-
 
g
 
–producing cells (Fig. 1, A
and B). The number of MP-specific effectors reached a na-
dir 7–30 d after immunization and improved thereafter. In
contrast, there was little decline in total influenza effector T
 
Table I.
 
Characteristics of DCs
 
DC Percentage large cells expressing:
ID HLA A2.1 Antigens Maturity Route Purity
 
*
 
HLADR
 
1
 
CD83
 
1
 
CD14
 
1
 
%
 
Im1
 
1
 
KLH, MP Immature s.c. 87 91 7 2
Im2
 
1
 
KLH, MP Immature s.c. 76 100 3 1
M1
 
2
 
KLH Mature i.d. 87 99 93 1
M2
 
2
 
KLH Mature s.c. 96 100 92 0
ID, subject identification.
 
*
 
Percent DCs by morphology. Dose of DCs injected in all subjects (after accounting for purity) was 2 
 
3
 
 10
 
6
 
 DCs. 
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Figure 1. Immune responses in uncultured T cells. (A and B) MP-,
gag-, and influenza (Flu)-specific IFN-g–producing cells from before
and after DC immunization were quantified in freshly isolated uncul-
tured PBMCs using an ELISPOT assay. Data for influenza specific
cells is per 105 cells. SEM for all measurements is ,20%. (A) Im1; (B)
Im2. (C and D). Pre- and postimmunization samples were thawed together and assayed for antigen-specific T cells secreting IFN-g, IL-4, and IL-10 us-
ing a 16-h ELISPOT assay. Antigens were HLA A2.1–restricted peptides from influenza MP, HIV-gag (gag), and CMV pp65 (CMV). Positive controls
for the assays included SEA for IFN-g and IL-10 and PHA for IL-4 (not shown). SEM for all measurements is ,20%. (C) Im1; (D) Im2. (E) Use of pep-
tide-pulsed DCs as APCs in the ELISPOT. Pre- and postimmunization specimens were examined using peptide-pulsed mature DCs as APCs (PBMC/
DC ratio 30:1) in the ELISPOT. SEM for all measurements is ,20%. (F) Quantification of MP-specific T cells using MHC tetramers in uncultured cells.
Pre-/postimmunization specimens were stained with A*0201–MP tetramers at 378C and analyzed by flow cytometry. Data shown are gated for CD81 T
cells and expressed as percent CD81 T cells binding A*0201–MP tetramer. 
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cell function, indicating that the decrease in MP effector
function was specific for the immunizing peptide. Similar
data were obtained when cryopreserved cells were assayed
together (Fig. 1, C and D), although the absolute reactivity
was higher with fresh cells, as reported previously (4). As a
control, no decline in antigen-specific IFN-
 
g
 
–producing
cells to HLA A
 
*
 
0201–restricted CMV peptide was ob-
served. The loss of MP-specific IFN-
 
g
 
–producing cells
persisted, even when peptide-pulsed mature DCs were
used as APCs in the ELISPOT (Fig. 1 E). In fact, the use of
DCs increased the preimmunization measurements, so that
the decrease in effectors after immature DC injection was
even more striking.
 
Induction of Antigen-specific IL-10–producing Cells In Vivo.
 
The decline in MP-specific IFN-
 
g
 
–producing cells was as-
sociated with the appearance of MP-specific IL-10– but
not IL-4–producing T cells (Fig. 1, C and D). No induc-
tion of IL-4/IL-10–producing cells to the control antigen
CMV was observed. The preimmunization IFN-
 
g
 
 secre-
tors and postimmunization IL-10 producers were both
CD8
 
1
 
CD4
 
2
 
, as indicated by magnetic bead depletion ex-
periments (not shown). MP-specific CD8
 
1
 
 T cells elicited
after mature DC injection in an earlier study (4) failed to
produce IL-10 (not shown), so we propose that the induc-
tion of IL-10 producers is due to the use of immature DCs.
 
Decline of Effectors Is Not Due to Loss of Circulating MP-spe-
cific T Cells.
 
The decline in MP (but not CMV or influ-
enza specific effectors) after immunization with MP-pulsed
immature DCs raised several possible mechanisms: imma-
ture DCs could lead to the loss of circulating MP-specific
T cells due to either cell death/deletion, or these cells may
redistribute to tissues/nodes after activation in vivo. Alter-
natively, DC injection could lead to inhibition of effector
T cell function or induction of anergy in an antigen-spe-
cific manner. Analysis of MP-specific T cells by MHC tet-
ramer binding in uncultured PBMCs revealed either no
change (Im1) or an increase (Im2) in MP-specific T cells
after DC immunization (Fig. 1 F). Therefore, the loss of ef-
fector function after immunization with immature DCs is
not due to a loss of circulating antigen-specific T cells.
 
Expansion of Memory T Cells with Defective Effector Function
In Vivo.
 
When pre- and postimmunization samples were
thawed together and boosted in culture with MP-pulsed
autologous mature DCs, there was a greater number of
MP-specific MHC tetramer binding T cells in postimmu-
nization cultures (Fig. 2 A). However, these specific anti-
Figure 2. (A–C) T cell recall assays in culture after DC immunization.
Pre- and postimmunization specimens were thawed and cocultured with
MP-pulsed DCs (unpulsed DCs as controls) for 7 d. After 7-d culture,
MP-specific T cells were quantified by MHC tetramers (A), ELISPOT
(B), and CTL assay (C). (A) MHC tetramer assay. Data are expressed as
percent CD81 T cells binding A*0201–MP tetramer. (B) ELISPOT assay.
On day 7, cells were transferred to an ELISPOT plate and restimulated
(Restim) overnight with specific antigen (10 mg/ml MP) or left without
restimulation (as controls), and antigen-specific IFN-g–producing cells
were quantified using an ELISPOT. SEM for all measurements is ,30%.
(C) CTL assay. MP-specific lysis was measured using MP-pulsed T2 tar-
gets. Data shown are after subtracting lysis with control unpulsed T2 tar-
gets and from cells after expansion using unpulsed DCs. 
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gen–binding T cells had reduced MP-specific IFN-
 
g
 
 pro-
ducers in the ELISPOT assay (Fig. 2 B) and failed to kill
peptide-pulsed targets (Fig. 2 C), even when they consti-
tuted up to 60% of all CD8
 
1
 
 T cells. There was no expan-
sion of MP-specific IL-10– or IL-4–producing T cells in
these cultures (not shown). We conclude that immuniza-
tion with immature antigen-bearing DCs blunts the capac-
ity of the corresponding antigen-specific CD8
 
1
 
 T cell to
mount lytic function in vitro.
 
Priming of KLH-specific T Cells In Vivo.
 
The two vol-
unteers immunized with mature DCs (M1, M2) were not
HLA A2.1
 
1
 
 and therefore could not be studied for their re-
sponse to the influenza MP peptide. However, cryopre-
served samples of PBMCs from all volunteers were assayed
together for KLH-specific proliferative responses. All sam-
ples showed strong responses to a superantigen used as a
positive control, but the KLH priming was much greater
when mature DCs had been used (Fig. 3 A). Small prolifer-
ative responses to KLH were noted in freshly thawed spec-
imens after immature DC injections (not shown), but no
KLH-specific IFN-
 
g
 
–secreting cells were evident, in con-
trast to clear Th1 priming with mature DCs (Fig. 3 B).
Therefore, the primary CD4 T cell responses were weaker
when immature DCs were used to immunize to KLH.
 
Discussion
 
In this study, we have shown that injection of antigen-
bearing immature DCs in humans is not immunologically
silent but can lead to antigen-specific inhibition of preexist-
ing effector T cell function. Moreover, T cells secreting an
immunosuppressive cytokine, IL-10, can be induced by
immature DCs (7). Immature DCs are thus not simply
weaker adjuvants and they do activate the immune system,
as indicated by the expansion of MP-specific tetramer–
binding CD8
 
1
 
 T cells in vivo. However, while these anti-
gen-binding T cells did retain in vitro
 
 
 
proliferative poten-
tial typical of memory T cells, they were defective in IFN-
 
g
 
secretion and lacked killer function.
To our knowledge, this is first report describing the in-
duction of antigen-specific IL-10–producing CD8
 
1
 
 T cells
in vivo
 
 
 
in humans. CD4
 
1
 
 T cells producing IL-10 have
been proposed to act as regulatory T cells in vivo (7). Inter-
estingly, there is a study of IL-10 function in culture show-
ing that IL-10 allows T cell proliferation but dampens their
effector function (8), a situation that occurred here. Neu-
tralization of IL-10 in culture in this study led to some im-
provement but 
 
,
 
50% reversal of the T cell inhibition (data
not shown), suggesting that both IL-10–dependent and
–independent mechanisms may play a role in the inhibition
of CD8
 
1
 
 T cell function observed here.
Induction of IL-10–producing CD4
 
1
 
 T cells with regu-
latory properties by repetitive stimulation with immature
DCs was recently observed by Jonuleit et al., another
group studying mixed lymphocyte reaction in vitro, in the
November 6 issue (reference 9). Although the immature
DCs that we injected were also pulsed with KLH, we were
unable to detect KLH-specific IL-10–producing CD4
 
1
 
 T
cells in this study. We cannot exclude the possibility that
this may relate to the low frequency of such cells after a
single DC injection or the fact that we were measuring
priming of a CD4
 
1
 
 T cell response.
It has been proposed that immature DCs carrying cellu-
lar antigens (e.g., phagocytosed apoptotic cells) might elicit
tolerance to naive peripheral T cells in vivo (10, 11). Our
findings surprisingly reveal that immature DCs can dampen
preexisting antigen-specific effector T cell function. Re-
sponses to immature DCs bearing tumor/viral antigens in
vivo can therefore help explain the occasional observation
of dysfunctional T cells in humans and mice (12–14), par-
Figure 3. Priming of KLH-specific T cells in vivo. (A) Antigen-dependent proliferation. Pre- and postimmunization PBMCs were thawed together
and cultured in the absence or presence of KLH (10 mg/ml). Data shown are KLH-specific proliferation after subtracting [3H]TdR incorporation in con-
trol wells. SEM for all measurements is ,30%. (B) KLH-specific IFN-g– and IL-4–producing cells from before and after DC immunization were quan-
tified in freshly isolated uncultured PBMCs using an ELISPOT assay. KLH-specific SFCs were calculated after subtracting data from control wells with-
out antigen.238 Inhibition of T Cell Function by Dendritic Cells
ticularly in the setting of deficient CD41 T cell function or
malignancy, which may affect DC maturation in vivo (15,
16).
DCs are currently under active clinical investigation,
mostly for their immunostimulatory properties in cancer
and viral infections (17). The optimal DC maturation stage
for these studies has yet to be fully established. Our data
urge caution with the use of immature DCs when trying to
enhance tumor and microbial immunity. On the other
hand, the suppressive properties of immature DCs ob-
served here should be pursued for antigen-specific inhibi-
tion of T cell function in the setting of autoimmune
diseases and organ transplantation in humans. Indeed, im-
mature DCs have been shown to prolong allograft survival
in several preclinical models (18). DCs have been injected
without ex vivo maturation stimulus in other clinical stud-
ies, however this has been done mostly in the context of
tumor antigens, wherein the preexisting effector function
is low or absent (17).
We were unable to continue injection of MP-pulsed im-
mature DCs in this study due to the potential for a reduc-
tion in influenza-specific effectors in our study subjects.
While we are now pursuing similar experiments in mice, it
is notable that there are significant differences in the degree
of spontaneous maturation in human and mouse DC cul-
tures, making the mouse a more difficult system to exploit
(1). Further studies in clinically appropriate settings are be-
ing designed to assess if injection of immature DCs can si-
lence autoreactive T cells in vivo.
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